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Abstract
Background: Sodium-channel myotonia (SCM) is a nondystrophic myotonia, characterized by pure myotonia
without muscle weakness or paramyotonia. The prevalence of skeletal muscle channelopathies is approximately 1 in
100,000, and the prevalence of SCM is much lower. To our knowledge, this is the first report on anesthetic
management of a patient with SCM.
Case presentation: A 23-year-old woman with congenital nasal dysplasia and SCM was scheduled to undergo
rhinoplasty with autologous costal cartilage. Total intravenous anesthesia without muscle relaxants was
administered followed by continuous intercostal nerve block. Although transient elevation of potassium level in the
blood was observed during surgery, the patient did not show exacerbation of myotonic or paralytic symptoms in
the postoperative period.
Conclusion: Total intravenous anesthesia and peripheral nerve block can be administered safely to a patient with
SCM. However, careful monitoring of the symptoms and electrolytes is recommended.
Keywords: Anesthetic management, Myotonia congenita, Nondystrophic myotonia, Paramyotonia congenita,
Periodic paralysis, Potassium-aggravated myotonia, Skeletal muscle channelopathy, Sodium-channel myotonia
Background
Sodium-channel myotonia (SCM) belongs to a group of
nondystrophic myotonias and is caused by mutations in
the sodium-channel gene on chromosome 17q, encoding
the α-subunit protein of the voltage-gated sodium chan-
nel Nav1.4 (SCN4A) expressed in the skeletal muscle [1].
It is characterized by pure myotonia, without muscle
weakness or paramyotonia, and is triggered by exercise
and the ingestion of potassium-rich food [1]. In patients
with SCM, special attention must be paid to the choice
of anesthetic agents, surgical pain management, and
body temperature management as all of these affect
muscle contraction. Because the prevalence of skeletal
muscle channelopathies is approximately 1 in 100,000
and that of SCM is much less [2], little is known about
how to safely administer anesthesia to these patients [3].
In fact, our literature search failed to yield any clinical
reports on the anesthetic management of patients with
SCM. Herein, we report the anesthetic management of a
patient diagnosed with SCM.
Case presentation
The patient was a 23-year-old woman (height 147.6 cm,
weight 43.5 kg) with congenital nasal dysplasia (Binder
syndrome). At the age of 3 years, the patient struggled to
initiate walking and to climb the stairs; additionally, she
exhibited grip myotonia and struggled to open her eyes
and mouth after sneezing. Exercise and cold exposure
induced symptom exacerbation. The patient’s mother
and younger sister also exhibited similar symptoms. The
patient was referred to our hospital, but after physical
examination, she was not definitively diagnosed with a
myotonic syndrome. She was followed up. At the age of
8 years, the patient underwent rhinoplasty with iliac
bone graft under general anesthesia without complica-
tions. At the age of 10 years, the patient underwent pos-
terior cervical fixation (C1–2) for traumatic atlantoaxial
subluxation under general anesthesia. However, when
the patient was extubated following surgery, she exhib-
ited acute dyspnea in the operating room and was im-
mediately re-intubated and transferred to the intensive
care unit. After discharge, the patient visited our hospital
again and genetic analysis revealed a mutation at V445M
in the SCN4A gene, leading to a diagnosis of SCM. As
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the patient grew, the nasal deformity became conspicu-
ous with increasing atrophy of the graft. Therefore, the
patient was scheduled to undergo a second rhinoplasty
with autologous costal cartilage.
Pre-operative test results, including those of blood
screening, blood gas analysis, X-ray examination, re-
spiratory function test, and electrocardiogram, were
within normal limits. The patient’s SCM-related symp-
toms were stable. Mexiletine and eperisone were taken
as needed. General anesthesia was induced with target-
controlled infusion of propofol (5 μg mL− 1), continuous
infusion of remifentanil (0.3 μg kg− 1 min− 1), and fen-
tanyl (200 μg), without any muscle relaxants. Due to the
posterior fixation of the patient’s cervical spine, a
McGrath® video laryngoscope (Covidien, Japan) was
used. Orotracheal intubation was performed without in-
ducing a cough reflex. Anesthesia was maintained with
propofol (2–2.4 μg mL− 1), remifentanil (0.1–0.25 μg kg−
1 min− 1), and fentanyl (300 μg). Arterial blood pressure
and BIS® index (Covidien, Japan) were monitored in
addition to standard monitoring. Body temperature at
the bladder was maintained between 36.0 and 37.4 °C
with a forced-air warming system.
As shown in Fig. 1 and Table 1, the blood concentration
of potassium ion rose during general anesthesia. After
changing Ringer’s solution to a potassium-free fluid, the
blood concentration of potassium ion returned to within
the normal range without any additional therapeutic inter-
vention. For postoperative analgesia, intercostal nerve
block with 10mL of 0.75% ropivacaine was administered
through a catheter (Perifix® ONE catheter, B. Braun,
Japan). Continuous infusion of 0.2% ropivacaine was
started at 4mL/h after the operation. Intraoperative car-
diovascular and respiratory vital signs remained stable.
After the operation was concluded, we exchanged the oro-
tracheal tube for a supraglottic airway device (Air-Q™
#3.5, Intermed Japan, Japan). The supraglottic airway de-
vice was removed uneventfully after we confirmed that
the patient had regained consciousness and initiated spon-
taneous breathing. The patient did not exhibit shivering
or exacerbation of other symptoms related to SCM. The
patient was transferred to the intensive care unit overnight
Fig. 1 Anesthesia record of the present case. BP, blood pressure (left axis); E, extubation; G1–7, the time points of arterial blood gas analysis; HR,
heart rate (left axis); I, intubation; TBLAD, urinary bladder temperature (right axis); ×, start and end of the anesthesia; ○, start and end of
the surgery
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and was discharged from the hospital on postoperative
day 7.
Discussion
Skeletal muscle channelopathies are divided into periodic
paralyses and nondystrophic myotonias [1]. Nondy-
strophic myotonia is characterized by muscle stiffness on
voluntary movement owing to delayed skeletal muscle re-
laxation. Nondystrophic myotonias include myotonia con-
genita, paramyotonia congenita, and SCM. Because SCM
is very rare, there have been no reports describing peri-
operative anesthetic management of patients with SCM to
date. For guidance, we referred to reports on anesthetic
management of patients with myotonic dystrophy and
other types of skeletal muscle channelopathies.
First, the anesthetic to be used was considered. Pre-
vious reports on the anesthetic management of pa-
tients with myotonic dystrophy and myotonia
congenita [4–7] suggest that propofol can be used
safely for induction and maintenance of general
anesthesia in patients with SCM. Volatile agents, in-
cluding sevoflurane and desflurane, may also be safe
for use in patients with SCM because they are not
contraindicated in patients with myotonic dystrophy
and other myotonic diseases [3, 7, 8]. However, de-
polarizing muscle relaxants must be avoided because
they may cause exaggerated contracture, masseter
spasm, and laryngospasm, thus complicating extuba-
tion [3, 7]. The use of non-depolarizing muscle
relaxants may be acceptable with monitoring of neuro-
muscular blockade [4], although the use of cholin-
esterase inhibitors might worsen the symptoms of
SCM as it does in other myopathies. In the present
case, we avoided muscle relaxants because we antici-
pated that the patient’s rhinoplasty and potential ex-
acerbation of myotonia would independently increase
the difficulty of her airway postoperatively.
An increase of serum potassium was noted during
anesthesia, which might result from the potassium-
containing solution and its redistribution [9]. It was rap-
idly decreased after switching it to a potassium-free solu-
tion. The mutation at V445M causes some alternations
in the gating mechanism of NaV1.4 as impairment of
fast inactivation and enhanced slow inactivation result in
increased excitability of the muscles [10]. Additionally,
pain or hypothermia can cause muscle contraction with
excessive sodium influx in patients with SCM, which
may result in an elevation of the extracellular potassium
level. Thus, repeated intraoperative arterial blood gas
analysis is recommended.
We made a concerted effort to prevent our patient from
shivering, because shivering can exacerbate symptoms of
myotonia [4]. This required particular focus on body
temperature control and pain management. We rewarmed
the patient and maintained her body temperature using a
forced-air warming device throughout the surgery. To
control pain, we administered intravenous fentanyl with a
continuous intercostal nerve block, bearing in mind that
excessive fentanyl during anesthesia should be avoided for
patients with difficult airways. Combined use of regional
anesthesia should be considered, if possible, in order to re-
duce opioid dose.
Oral administration of mexiletine might be used if the
patient had an acute myotonic episode, because it is gen-
erally regarded as the only effective treatment for myo-
tonic episodes [11]. It is a non-selective sodium channel
inhibitor and belongs to the Vaughan-Williams class IB
anti-arrhythmic group of drugs [12]. Although IB and IC
anti-arrhythmic group of drugs have been studied, no
other drug has been shown effective for treatment of
myotonia. Additionally, the effectiveness of intravenous
mexiletine is unknown. Usually myotonia lasts for sec-
onds to minutes and improves with time; however,
sometimes it lasts longer and involves respiratory and/or
Table 1 Results of arterial blood gas analysis
Pre-op G1 G2 G3 G4 G5 G6 G7 Post-op
pH 7.41 7.41 7.40 7.43 7.45 7.41 7.42 7.43 7.41
pCO2 (mmHg) 41.1 35.9 36.1 33.7 31.6 35.0 34.9 35.1 38.2
pO2 (mmHg) 100 334 273 274 239 273 267 265 132
HCO3
− (mEq/L) 25.5 22.2 21.8 22.0 21.4 22.0 22.5 23.0 23.7
BE (mEq/L) 1.3 −1.5 −2.0 −1.2 − 1.5 −1.6 − 1.0 − 0.4 − 0.3
Hb (g/dL) 12.3 11.1 11.0 11.3 11.3 11.1 10.6 10.6 11.6
Glu (mg/dL) NA 109 125 99 98 128 112 84 89
Na+ (mEq/L) 140 139 142 141 142 141 143 144 137
K+ (mEq/L) 3.8 3.5 3.4 5.2 5.4 4.9 3.5 3.1 3.4
Cl− (mEq/L) 107 109 111 113 116 114 115 115 108
Ca2+ (mEq/L) 1.21 1.15 1.15 1.17 1.15 1.16 1.14 1.16 1.16
BE base excess. G1–7: time points of these analyses are shown in Fig. 1
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swallowing muscles. Therefore, we need to observe the
patient carefully for signs of deterioration postopera-
tively [13]. Intensive treatment, including constant moni-
toring, is definitely required for patients with SCM after
general anesthesia. The patient should be followed up
for several hours after extubation in a postanesthesia
care unit [14]. In addition, we need to provide preopera-
tive education to the patient to enable self-recognition
of worsening myotonia and notify the medical staff for
help.
The present patient had a history of re-intubation fol-
lowing postoperative respiratory failure. For this reason,
we decided to exchange the device used for airway main-
tenance as described above. Supraglottic airway devices
allow cautious observation of respiratory conditions
without tracheal stimulation [15], which can trigger
myotonia in patients with SCM. This procedure should
be considered for patients requiring tracheal intubation.
In conclusion, we safely administered total intraven-
ous anesthesia to a patient with SCM, although the
current literature does not present contraindications
to the use of inhaled anesthetics in these patients.
Given the clinical course of the present patient, close
monitoring of electrolytes, airway patency, and symp-
toms is recommended.
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